{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:29:16Z","timestamp":1787243356616,"version":"build-2736575974"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In recent years, lecanemab received regulatory approval from several regulatory agencies. The safety profile, particularly the risk of amyloid-related imaging abnormalities (ARIA), necessitates post-marketing surveillance. From a public health perspective, generating robust real-world evidence (RWE) is essential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aims to inform policy and clinical decision-makers by analyzing prescribing information, literature evidence, and the FDA Adverse Events Reporting System (FAERS) pharmacovigilance reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study employed a mixed-method approach. First, prescribing information for lecanemab was collected and compared across four regulatory agencies. Second, a systematic literature review was conducted in MEDLINE and Embase to identify RWE studies reporting adverse events (AEs), symptoms, or management strategies in patients treated with lecanemab. Finally, post-marketing safety data from the FAERS database were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four regulatory agencies have approved lecanemab through different pathways, each requiring confirmation of amyloid pathology and careful assessment of ARIA risk, particularly in Apolipoprotein E (ApoE) \u03b54 homozygotes. Notable differences exist across agencies regarding indications, contraindications, monitoring protocols, and criteria for treatment suspension, resumption, or discontinuation. All authorities mandate post-marketing programs to ensure ongoing monitoring of safety and effectiveness.<\/jats:p>\n                    <jats:p>A bibliographic search identified 26 studies. Nine cohort studies included between 19 and 407 participants and reported follow-up periods ranging from 6 to 14\u00a0months; in a few studies, lecanemab was administered to individuals with moderate or severe AD. As expected, infusion-related reactions (IRRs) and ARIA were the most frequent adverse events, predominantly occurring within the first seven infusions. Some studies reported preliminary efficacy outcomes, although attrition bias may have affected these findings. Seventeen case reports described nineteen individuals aged 57\u201382, with most AEs arising between the 3rd and 7th infusion and primarily consisting of ARIA; serious events such as stroke, seizures, and two fatalities were also noted. In most cases, lecanemab was paused or permanently discontinued.<\/jats:p>\n                    <jats:p>Analysis of the FAERS database identified 1,286 reports revealing 2,627 AEs, of which 30% were classified as serious, including forty-six deaths. The most reported AEs were headache, ARIA-E, ARIA-H, and chills. ARIA-E and ARIA-H have similar demographics, onset timing, and severity profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study highlights the complexity of lecanemab\u2019s safety profile and the variability in regulatory prescribing recommendations. While ARIA, especially in ApoE \u03b54 homozygotes, remains the most frequent adverse event, its severity ranges from mild to, in rare cases, severe or fatal. These findings underscore the need for robust post-marketing surveillance and harmonized recommendations to ensure safe and effective clinical use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10072-026-08829-4","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:27:33Z","timestamp":1772756853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Regulatory, clinical, and post-marketing challenges of lecanemab for Alzheimer\u2019s disease: insights from real-world data"],"prefix":"10.1007","volume":"47","author":[{"given":"Giuseppe","family":"Marano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Da Cas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Ippoliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Caffarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Locuratolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-3758","authenticated-orcid":false,"given":"Nicola","family":"Vanacore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ancidoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"8829_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/brain\/awad005","volume":"146","author":"R Perneczky","year":"2023","unstructured":"Perneczky R, Jessen F, Grimmer T et al (2023) Anti-amyloid antibody therapies in Alzheimer\u2019s disease. Brain 146:842\u2013849. https:\/\/doi.org\/10.1093\/brain\/awad005","journal-title":"Brain"},{"key":"8829_CR2","unstructured":"Cavazzoni P (2021) FDA\u2019s Decision to Approve New Treatment for Alzheimer\u2019s Disease | FDA. https:\/\/www.fda.gov\/drugs\/our-perspective\/fdas-decision-approve-new-treatment-alzheimers-disease. Accessed 14 July 2025."},{"key":"8829_CR3","unstructured":"European Medicines Agency (EMA). (2021) Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13\u201316 December 2021. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021. Accessed 14 July 2025."},{"key":"8829_CR4","unstructured":"US Food and Drug Administration (FDA). (2023) FDA Converts Novel Alzheimer\u2019s Disease Treatment to Traditional Approval. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval. Accessed 14 July 2025."},{"key":"8829_CR5","unstructured":"European Medicines Agency (EMA). (2024). Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11\u201314 November 2024 | European Medicines Agency (EMA). Accessed 14 July 2025."},{"key":"8829_CR6","unstructured":"European Medicines Agency (EMA). (2025). Meeting highlights from the\u00a0Committee for Medicinal Products for Human Use\u00a0(CHMP) 21\u201324 July 2025. Accessed 28 July 2025."},{"key":"8829_CR7","unstructured":"Gov UK (2024) Lecanemab licensed for adult patients in the early stages of Alzheimer\u2019s disease https:\/\/www.gov.uk\/government\/news\/lecanemab-licensed-for-adult-patients-in-the-early-stages-of-alzheimers-disease. Accessed 14 July 2025."},{"key":"8829_CR8","unstructured":"Gov UK (2024) Donanemab licensed for early stages of Alzheimer\u2019s disease in adult patients who have one or no copies of apolipoprotein E4 gene. https:\/\/www.gov.uk\/government\/news\/donanemab-licensed-for-early-stages-of-alzheimers-disease-in-adult-patients-who-have-one-or-no-copies-of-apolipoprotein-e4-gene. Accessed 14 July 2025."},{"key":"8829_CR9","unstructured":"National Institute for Health and Care Excellence (NICE) (2025) Final draft guidance Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer\u2019s disease. https:\/\/www.nice.org.uk\/guidance\/gid-ta11220\/documents\/674. Accessed 14 July 2025."},{"key":"8829_CR10","unstructured":"National Institute for Health and Care Excellence (NICE) (2025) Final draft guidance Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease. https:\/\/www.nice.org.uk\/guidance\/gid-ta11221\/documents\/674. Accessed 14 July 2025."},{"issue":"2","key":"8829_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F et al (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 9(2):197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"8829_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.14283\/jpad.2023.6","volume":"10","author":"C Mallinckrodt","year":"2023","unstructured":"Mallinckrodt C, Tian Y, Aisen PS et al (2023) Investigating partially discordant results in phase 3 studies of aducanumab. J Prev Alzheimers Dis 10(2):171\u2013177. https:\/\/doi.org\/10.14283\/jpad.2023.6","journal-title":"J Prev Alzheimers Dis"},{"key":"8829_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"issue":"18","key":"8829_CR14","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C et al (2021) Donanemab in early Alzheimer\u2019s disease. N Engl J Med 384(18):1691\u20131704. https:\/\/doi.org\/10.1056\/NEJMoa2100708","journal-title":"N Engl J Med"},{"issue":"6","key":"8829_CR15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6):512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"issue":"1","key":"8829_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01669-4","volume":"17","author":"X Xing","year":"2025","unstructured":"Xing X, Zhang X, Wang K et al (2025) Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database. Alzheimers Res Ther 17(1):15. https:\/\/doi.org\/10.1186\/s13195-024-01669-4","journal-title":"Alzheimers Res Ther"},{"key":"8829_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jad.2025.01.022","volume":"374","author":"Z Li","year":"2025","unstructured":"Li Z, Gu J, Du Z, Lu R, Jiang Y, Zhu H (2025) Characteristics of adverse events and clinical risks of Lecanemab based on FAERS data. J Affect Disord 374:46\u201354. https:\/\/doi.org\/10.1016\/j.jad.2025.01.022","journal-title":"J Affect Disord"},{"issue":"3","key":"8829_CR18","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1177\/13872877241307246","volume":"103","author":"W Ge","year":"2025","unstructured":"Ge W, Yan Y, Hu Y, Lin S, Mao P (2025) Unveiling the safety profile of lecanemab: a comprehensive analysis of adverse events using FDA adverse event reporting system data. J Alzheimers Dis 103(3):844\u2013855. https:\/\/doi.org\/10.1177\/13872877241307246","journal-title":"J Alzheimers Dis"},{"key":"8829_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1559447","volume":"16","author":"L Yan","year":"2025","unstructured":"Yan L, Zhang L, Xu Z, Luo Z (2025) A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab. Front Pharmacol 16:1559447. https:\/\/doi.org\/10.3389\/fphar.2025.1559447","journal-title":"Front Pharmacol"},{"issue":"3","key":"8829_CR20","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1177\/13872877251333084","volume":"105","author":"J Li","year":"2025","unstructured":"Li J, Zhang F, Eisel UL (2025) Adverse events associated with lecanemab: a disproportionality analysis of data from the FDA adverse event reporting system. J Alzheimers Dis 105(3):849\u2013859. https:\/\/doi.org\/10.1177\/13872877251333084","journal-title":"J Alzheimers Dis"},{"key":"8829_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1561020","volume":"16","author":"H Hu","year":"2025","unstructured":"Hu H, Zhao Y, Mao J, He J, Zhang Y, Ye H, Yang X (2025) A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases. Front Pharmacol 16:1561020. https:\/\/doi.org\/10.3389\/fphar.2025.1561020","journal-title":"Front Pharmacol"},{"key":"8829_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1593989","volume":"16","author":"L Kong","year":"2025","unstructured":"Kong L, Yang X, Xu J (2025) Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system. Front Pharmacol 16:1593989. https:\/\/doi.org\/10.3389\/fphar.2025.1593989","journal-title":"Front Pharmacol"},{"key":"8829_CR23","unstructured":"US Food & Drug Administration. FDA Adverse Event Reporting System (FAERS) Quarterly Data Extract Files. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files. Accessed 14 July 2025."},{"key":"8829_CR24","unstructured":"US Food and Drug Administration (FDA). (2025) Leqembi label. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Accessed 14 July 2025."},{"key":"8829_CR25","unstructured":"European Medicines Agency (EMA). (2025) Leqembi: EPAR - Product information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/leqembi. Accessed 14 July 2025."},{"key":"8829_CR26","unstructured":"Electronic medicines compendium (emc) (2025) Leqembi Healthcare Professionals (SmPC). https:\/\/www.medicines.org.uk\/emc\/product\/15908\/smpc\/print Accessed 14 July 2025."},{"key":"8829_CR27","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). (2023) Leqembi Report on the Deliberation Results. https:\/\/www.pmda.go.jp\/files\/000267068.pdf Accessed 14 July 2025."},{"key":"8829_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3701","author":"E Potter","year":"2025","unstructured":"Potter E, Reyes M, Naples J, Dal Pan G (2025) FDA adverse event reporting system (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS. Clin Pharmacol Ther. https:\/\/doi.org\/10.1002\/cpt.3701","journal-title":"Clin Pharmacol Ther"},{"key":"8829_CR29","unstructured":"Maintenance and Support Services Organization. Medical Dictionary for Regulatory Activities https:\/\/www.meddra.org (2024) Accessed 14 July 2025."},{"issue":"2","key":"8829_CR30","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1177\/13872877251361051","volume":"107","author":"H Arai","year":"2025","unstructured":"Arai H, Aiba S, Arai R (2025) Safety of switching from lecanemab to donanemab in 20 consecutive patients with Alzheimer\u2019s disease. J Alzheimers Dis 107(2):494\u2013495. https:\/\/doi.org\/10.1177\/13872877251361051","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"8829_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70750","volume":"21","author":"S Chen","year":"2025","unstructured":"Chen S, Ou R, Wei Q et al (2025) Lecanemab treatment for Alzheimer\u2019s disease of varying severities and associated plasma biomarkers monitoring: a multi-center real-world study in China. Alzheimers Dement 21(10):e70750. https:\/\/doi.org\/10.1002\/alz.70750","journal-title":"Alzheimers Dement"},{"issue":"22","key":"8829_CR32","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1097\/CM9.0000000000003888","volume":"138","author":"W Kang","year":"2025","unstructured":"Kang W, Gao C, Li X et al (2025) Safety and effectiveness of lecanemab in Chinese patients with early Alzheimer\u2019s disease: evidence from a multidimensional real-world study. Chin Med J 138(22):2907\u20132916. https:\/\/doi.org\/10.1097\/CM9.0000000000003888","journal-title":"Chin Med J"},{"key":"8829_CR33","doi-asserted-by":"publisher","unstructured":"Li LL, Wang RZ, Wang Z, et al. (2025). Safety and short-term outcomes of lecanemab for Alzheimer's disease in China: a multicentre study. Brain awaf427 https:\/\/doi.org\/10.1093\/brain\/awaf427","DOI":"10.1093\/brain\/awaf427"},{"issue":"4","key":"8829_CR34","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1177\/13872877251366657","volume":"107","author":"N Mervosh","year":"2025","unstructured":"Mervosh N, Bilici N, Wisniewski T, Devi G (2025) Reducing ARIA risk in Alzheimer\u2019s disease: real-world impact of APOE genotype-guided slow titration with aducanumab and lecanemab. J Alzheimers Dis 107(4):1400\u20131403. https:\/\/doi.org\/10.1177\/13872877251366657","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"8829_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13142-9","volume":"272","author":"M Rosenbloom","year":"2025","unstructured":"Rosenbloom M, Schnee A, Nimma S, Lutz H, Gzesh D, Weisman D (2025) Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics. J Neurol 272(6):394. https:\/\/doi.org\/10.1007\/s00415-025-13142-9","journal-title":"J Neurol"},{"key":"8829_CR36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.1232","volume":"12","author":"M Paczynski","year":"2025","unstructured":"Paczynski M, Hofmann A, Posey Z et al (2025) Lecanemab treatment in a specialty memory clinic. JAMA Neurol 12:e251232. https:\/\/doi.org\/10.1001\/jamaneurol.2025.1232","journal-title":"JAMA Neurol"},{"issue":"6","key":"8829_CR37","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.14283\/jpad.2024.159","volume":"11","author":"LBE Shields","year":"2024","unstructured":"Shields LBE, Hust H, Cooley SD et al (2024) Initial experience with Lecanemab and lessons learned in 71 patients in a regional medical center. J Prev Alzheimers Dis 11(6):1549\u20131562. https:\/\/doi.org\/10.14283\/jpad.2024.159","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"8829_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-025-01763-1","volume":"17","author":"N Bregman","year":"2025","unstructured":"Bregman N, Nathan T, Shir D et al (2025) Lecanemab in clinical practice: real-world outcomes in early Alzheimer\u2019s disease. Alzheimers Res Ther 17(1):119. https:\/\/doi.org\/10.1186\/s13195-025-01763-1","journal-title":"Alzheimers Res Ther"},{"key":"8829_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/13554794.2025.2566151","author":"H Alammar","year":"2025","unstructured":"Alammar H, Diallo M, Llano DA (2025) Multiple ischemic strokes in a patient treated with Lecanemab: a case report. Neurocase. https:\/\/doi.org\/10.1080\/13554794.2025.2566151","journal-title":"Neurocase"},{"issue":"8","key":"8829_CR40","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.91230","volume":"17","author":"I Bitar","year":"2025","unstructured":"Bitar I, Alabdalrazzak M, Zamzam M, Desai Y, Abushaban K (2025) Clinically silent amyloid-related imaging abnormality with edema following Lecanemab therapy: a case report. Cureus 17(8):e91230. https:\/\/doi.org\/10.7759\/cureus.91230","journal-title":"Cureus"},{"key":"8829_CR41","doi-asserted-by":"publisher","DOI":"10.1177\/25424823251366998","volume":"9","author":"S Chen","year":"2025","unstructured":"Chen S, Sun Y, Yao L, Peng Q (2025) Probable lecanemab-associated pontine hemorrhage following cardiovascular intervention: clinical implications for lecanemab use. J Alzheimers Dis Rep 9:25424823251366998. https:\/\/doi.org\/10.1177\/25424823251366998","journal-title":"J Alzheimers Dis Rep"},{"key":"8829_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.70251","author":"H Hanyu","year":"2025","unstructured":"Hanyu H, Koyama Y, Momose T, Watanabe S (2025) Patient with mild Alzheimer\u2019s disease homozygous for ApoE \u03b54 showing improved cognition, no brain volume loss, and complete amyloid clearance after lecanemab treatment. Geriatr Gerontol Int. https:\/\/doi.org\/10.1111\/ggi.70251","journal-title":"Geriatr Gerontol Int"},{"key":"8829_CR43","doi-asserted-by":"publisher","unstructured":"Naeshiro Y, Kitani-Morii F, Kasai T, Tanaka E, Kobayashi F, & Ohara T (2025). Amyloid Clearance and Transient CSF A\u03b240 Reduction in a Case of ARIA-E\/H Following Lecanemab Treatment. Internal medicine https:\/\/doi.org\/10.2169\/internalmedicine.6070-25","DOI":"10.2169\/internalmedicine.6070-25"},{"issue":"10","key":"8829_CR44","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/phar.70060","volume":"45","author":"AN Navarra","year":"2025","unstructured":"Navarra AN, Wang LA, Al-Sahlani H, Liu AJ, Doraiswamy PM (2025) Severe persistent urinary retention following treatment with intravenous lecanemab. Pharmacotherapy 45(10):702\u2013705. https:\/\/doi.org\/10.1002\/phar.70060","journal-title":"Pharmacotherapy"},{"issue":"4","key":"8829_CR45","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200508","volume":"15","author":"NU Schwartz","year":"2025","unstructured":"Schwartz NU, Dietz CD, Prufer Ara\u00fajo I et al (2025) Changes of a cerebral cavernous malformation associated with lecanemab therapy in a patient with Alzheimer disease. Neurol Clin Pract 15(4):e200508. https:\/\/doi.org\/10.1212\/CPJ.0000000000200508","journal-title":"Neurol Clin Pract"},{"issue":"1","key":"8829_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-025-04302-5","volume":"25","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yu Q, Chen B et al (2025) Two cases of Amyloid-related imaging abnormalities (ARIA) following lecanemab treatment for alzheimer\u2019s disease and a literature review. BMC Neurol 25(1):281. https:\/\/doi.org\/10.1186\/s12883-025-04302-5","journal-title":"BMC Neurol"},{"key":"8829_CR47","doi-asserted-by":"publisher","DOI":"10.1177\/25424823251395615","volume":"9","author":"X Wang","year":"2025","unstructured":"Wang X, Liu Y, Fan S et al (2025) Combined 64-channel EEG and PET evaluation of lecanemab efficacy: two case reports. J Alzheimers Dis Rep 9:25424823251395615. https:\/\/doi.org\/10.1177\/25424823251395615","journal-title":"J Alzheimers Dis Rep"},{"issue":"1","key":"8829_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-025-06445-z","volume":"25","author":"M Zou","year":"2025","unstructured":"Zou M, Xu SS, Zhu SG, Yuan CX, Huang JF, Zhu JH, Zhang X, Wang JY (2025) Elevated D-dimer levels after lecanemab infusions: a case report. BMC Geriatr 25(1):742. https:\/\/doi.org\/10.1186\/s12877-025-06445-z","journal-title":"BMC Geriatr"},{"issue":"1","key":"8829_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2024-263497","volume":"18","author":"M Watanabe","year":"2025","unstructured":"Watanabe M, Okochi R, Tezuka T, Ito D (2025) Spontaneous haemorrhage in subdural hygroma in an Alzheimer\u2019s patient on lecanemab. BMJ Case Rep 18(1):e263497. https:\/\/doi.org\/10.1136\/bcr-2024-263497","journal-title":"BMJ Case Rep"},{"issue":"11","key":"8829_CR50","doi-asserted-by":"publisher","first-page":"8192","DOI":"10.1002\/alz.14223","volume":"20","author":"AW Gibson","year":"2024","unstructured":"Gibson AW, Elser H, Rosso M et al (2024) Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemab. Alzheimers Dement 20(11):8192\u20138197. https:\/\/doi.org\/10.1002\/alz.14223","journal-title":"Alzheimers Dement"},{"issue":"1","key":"8829_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01640-3","volume":"16","author":"S Ji","year":"2024","unstructured":"Ji S, Rosenbloom M (2024) Intracerebral hemorrhage following mild ARIA-H in an APOE \u03b52 carrier receiving lecanemab. Alzheimers Res Ther 16(1):265. https:\/\/doi.org\/10.1186\/s13195-024-01640-3","journal-title":"Alzheimers Res Ther"},{"key":"8829_CR52","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1111\/cen3.12821","volume":"15","author":"M Noguchi-Shinohara","year":"2024","unstructured":"Noguchi-Shinohara M, Komatsu J, Ono K (2024) Amyloid-related imaging abnormalities in a woman with apolipoprotein E \u03b54 homozygotes treated with lecanemab for Alzheimer\u2019s disease. Clin Exp Neuroimmunol 15:1759\u20131961. https:\/\/doi.org\/10.1111\/cen3.12821","journal-title":"Clin Exp Neuroimmunol"},{"key":"8829_CR53","doi-asserted-by":"publisher","DOI":"10.1111\/psyg.13231","volume":"25","author":"A Yamazaki","year":"2024","unstructured":"Yamazaki A, Sekine T, Takahashi S et al (2024) A case of severe ARIA with multiple infarctions and extensive microbleeds following lecanemab administration. Psychogeriatrics 25:e13231. https:\/\/doi.org\/10.1111\/psyg.13231","journal-title":"Psychogeriatrics"},{"issue":"5","key":"8829_CR54","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMc2215148","volume":"388","author":"NJ Reish","year":"2023","unstructured":"Reish NJ, Jamshidi P, Stamm B et al (2023) Multiple cerebral hemorrhages in a patient receiving Lecanemab and treated with t-PA for stroke. N Engl J Med 388(5):478\u2013479. https:\/\/doi.org\/10.1056\/NEJMc2215148","journal-title":"N Engl J Med"},{"issue":"1","key":"8829_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43933-5","volume":"14","author":"E Solopova","year":"2023","unstructured":"Solopova E, Romero-Fernandez W, Harmsen H et al (2023) Fatal iatrogenic cerebral \u03b2-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer\u2019s disease. Nat Commun 14(1):8220. https:\/\/doi.org\/10.1038\/s41467-023-43933-5","journal-title":"Nat Commun"},{"issue":"5","key":"8829_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100160","volume":"12","author":"C Chen","year":"2025","unstructured":"Chen C, Katayama S, Lee JH et al (2025) Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 12(5):100160. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100160","journal-title":"J Prev Alzheimers Dis"},{"issue":"12","key":"8829_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70905","volume":"21","author":"CH van Dyck","year":"2025","unstructured":"van Dyck CH, Sperling R, Johnson K et al (2025) Long-term safety and efficacy of lecanemab in early Alzheimer\u2019s disease: results from the clarity AD open-label extension study. Alzheimers Dement 21(12):e70905. https:\/\/doi.org\/10.1002\/alz.70905","journal-title":"Alzheimers Dement"},{"issue":"3","key":"8829_CR58","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD et al (2023) Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis 10(3):362\u2013377. https:\/\/doi.org\/10.14283\/jpad.2023.30","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"8829_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100094","volume":"12","author":"N Villain","year":"2025","unstructured":"Villain N, Planche V, Lilamand M et al (2025) Lecanemab for early Alzheimer\u2019s disease: appropriate use recommendations from the French federation of memory clinics. J Prev Alzheimers Dis 12(4):100094. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100094","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"8829_CR60","doi-asserted-by":"publisher","first-page":"165","DOI":"10.12779\/dnd.2024.23.4.165","volume":"23","author":"KH Park","year":"2024","unstructured":"Park KH, Kim GH, Kim CH et al (2024) Lecanemab: appropriate use recommendations by Korean Dementia Association. Dement Neurocogn Disord 23(4):165\u2013187. https:\/\/doi.org\/10.12779\/dnd.2024.23.4.165","journal-title":"Dement Neurocogn Disord"},{"issue":"1","key":"8829_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-025-01735-5","volume":"17","author":"X Xing","year":"2025","unstructured":"Xing X, Zhang X, Wang K, Wang Z, Feng Y, Li X, Hua Y, Zhang L, Dong X (2025) Post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database. Alzheimers Res Ther 17(1):92","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"8829_CR62","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.33218\/001c.92098","volume":"7","author":"FJ Thomas","year":"2024","unstructured":"Thomas FJ, Qayyum Sarguroh Khan MA, Khan RA, Patel SV (2024) Effectiveness of lecanemab on Alzheimer\u2019s disease. Precis Nanomed 7(1):1211\u20131220. https:\/\/doi.org\/10.33218\/001c.92098","journal-title":"Precis Nanomed"},{"issue":"10","key":"8829_CR63","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1038\/s43587-025-00980-5","volume":"5","author":"T Iwatsubo","year":"2025","unstructured":"Iwatsubo T (2025) A Japanese registry for optimizing the safe use of anti-amyloid therapies for Alzheimer\u2019s disease in Japan. Nat Aging 5(10):1917\u20131919. https:\/\/doi.org\/10.1038\/s43587-025-00980-5","journal-title":"Nat Aging"},{"issue":"1","key":"8829_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-025-01699-6","volume":"17","author":"M Donati","year":"2025","unstructured":"Donati M, Boccia A, De Ponti F, Poluzzi E, Raschi E (2025) Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance. Alzheimers Res Ther 17(1):80. https:\/\/doi.org\/10.1186\/s13195-025-01699-6","journal-title":"Alzheimers Res Ther"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-08829-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-08829-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-08829-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:27:13Z","timestamp":1781638033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-08829-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["8829"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-08829-4","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this paper has been updated to fix Supplementary File 2, in which the image was obscured or not displaying correctly online. In addition, the second affiliation of Dr Paolo Caffarra has been removed, as it was included in error.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the respective authors\u2019 organisations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimers"}},{"value":"The authors disclose no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"322"}}